Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer

19 Feb 2021

Abstract excerpt

Targeting mutated oncogenes is an effective approach for treating cancer. The 4 main driver genes of pancreatic ductal adenocarcinoma (PDAC) are KRAS, TP53, CDKN2A, and SMAD4, collectively called the "big 4" of PDAC, however they remain challenging therapeutic targets. In this study, ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 (ASAP2), one of the ArfGAP family, was identified as a novel driver gene in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Pancreatic and Hepatic Oncology Research
Share to Renal and related cancers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33605496
DOI: 10.1111/cas.14858

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The novel driver gene ASAP2 is a potential druggable target in pancreatic cancerPMID 33605496Read ↗

Identification of potential target genes in pancreatic ductal adenocarcinoma by bioinformatics analysisSemantic proximity Read ↗

Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDACSemantic proximity Read ↗

RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

GSK2126458 has the potential to inhibit the proliferation of pancreatic cancer uncovered by bioinformatics analysis and pharmacological experimentsSemantic proximity Read ↗

Gene Regulation by Antitumor miR-204-5p in Pancreatic Ductal Adenocarcinoma: The Clinical Significance of Direct RACGAP1 RegulationSemantic proximity Read ↗

Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapySemantic proximity Read ↗

Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancerSemantic proximity Read ↗

EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growthSemantic proximity Read ↗

Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21Semantic proximity Read ↗

Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene SignatureSemantic proximity Read ↗

Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.Semantic proximity Read ↗

PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.